Sale!

LAMA3 Gene Epidermolysis bullosa generalized atrophic benign Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The LAMA3 gene plays a crucial role in the development and integrity of the skin and mucous membranes. Mutations in this gene are associated with a rare genetic disorder known as Epidermolysis Bullosa Generalized Atrophic Benign (EBGAB). This condition is characterized by fragile skin that easily blisters and forms scars, often leading to significant discomfort and potential complications.

To diagnose this condition accurately, genetic testing for mutations in the LAMA3 gene is available. DNA Labs UAE offers a comprehensive genetic test designed to identify these specific mutations, providing essential information for diagnosis, management, and familial planning. The test is performed using a sample of the patient’s DNA, typically collected through a blood draw or cheek swab.

The cost of the LAMA3 gene genetic test at DNA Labs UAE is 4400 AED. This investment covers the meticulous process of extracting DNA, analyzing the specific regions of the LAMA3 gene for mutations, and interpreting the results to provide a conclusive report. This testing is crucial for affected individuals and their families to understand the genetic basis of the condition, inform treatment strategies, and assess the risk for future generations.

Given the complexity of genetic disorders like EBGAB, the insights gained from the LAMA3 gene test are invaluable for patients and healthcare providers, enabling personalized care plans and improving quality of life for those affected by this challenging condition.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

LAMA3 Gene Epidermolysis Bullosa Generalized Atrophic Benign Genetic Test

Introduction

The LAMA3 gene is associated with a genetic disorder called Epidermolysis bullosa (EB), specifically the generalized atrophic benign subtype. EB is a group of rare genetic disorders that affect the skin and cause it to be extremely fragile. People with EB have skin that is prone to blistering and tearing from minor friction or trauma.

The generalized atrophic benign subtype of EB is characterized by blistering and erosion of the skin, particularly in areas of high friction such as the hands, feet, knees, and elbows. However, unlike other subtypes of EB, the skin in generalized atrophic benign EB tends to heal without scarring. Additionally, this subtype is usually not associated with other complications or internal organ involvement.

Test Details

The LAMA3 Gene Epidermolysis bullosa generalized atrophic benign Genetic Test is a genetic test that analyzes the LAMA3 gene using NGS (Next-Generation Sequencing) technology. The test can detect variations or mutations in the LAMA3 gene that may be responsible for causing or contributing to the development of generalized atrophic benign EB.

By identifying the specific genetic mutation in the LAMA3 gene, NGS genetic testing can provide a definitive diagnosis of generalized atrophic benign EB. This information can be useful for understanding the underlying cause of the condition, predicting disease progression, and guiding treatment options and management strategies.

Test Components and Price

  • Test Name: LAMA3 Gene Epidermolysis bullosa generalized atrophic benign Genetic Test
  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Osteology Dermatology Immunology Disorders
  • Doctor: Dermatologist
  • Test Department: Genetics

Pre Test Information

A Genetic Counselling session is recommended to gather the clinical history of the patient who is going for the LAMA3 Gene Epidermolysis bullosa generalized atrophic benign NGS Genetic DNA Test. This session will also involve drawing a pedigree chart of family members affected with LAMA3 Gene Epidermolysis bullosa.

Conclusion

The LAMA3 Gene Epidermolysis bullosa generalized atrophic benign Genetic Test is an important tool in diagnosing and understanding the generalized atrophic benign subtype of Epidermolysis bullosa. By identifying the specific genetic mutation in the LAMA3 gene, this test can provide valuable information for disease management and treatment options.

Test Name LAMA3 Gene Epidermolysis bullosa generalized atrophic benign Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Osteology Dermatology Immunology Disorders
Doctor Dermatologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for LAMA3 Gene Epidermolysis bullosa, generalized atrophic benign NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with LAMA3 Gene Epidermolysis bullosa, generalized atrophic benign NGS Genetic DNA Test gene LAMA3
Test Details

The LAMA3 gene is associated with a genetic disorder called Epidermolysis bullosa (EB), specifically the generalized atrophic benign subtype. EB is a group of rare genetic disorders that affect the skin and cause it to be extremely fragile. People with EB have skin that is prone to blistering and tearing from minor friction or trauma.

The generalized atrophic benign subtype of EB is characterized by blistering and erosion of the skin, particularly in areas of high friction such as the hands, feet, knees, and elbows. However, unlike other subtypes of EB, the skin in generalized atrophic benign EB tends to heal without scarring. Additionally, this subtype is usually not associated with other complications or internal organ involvement.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that allows for the simultaneous analysis of multiple genes, including the LAMA3 gene. This test can detect variations or mutations in the LAMA3 gene that may be responsible for causing or contributing to the development of generalized atrophic benign EB.

By identifying the specific genetic mutation in the LAMA3 gene, NGS genetic testing can provide a definitive diagnosis of generalized atrophic benign EB. This information can be useful for understanding the underlying cause of the condition, predicting disease progression, and guiding treatment options and management strategies.